| Quarterly Financials | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 21 | 24 | 24 | 32 | 34 | 39 | 37 | 46 |
| Expenses | 16 | 20 | 18 | 24 | 26 | 29 | 29 | 36 |
| EBITDA | 5 | 4 | 5 | 8 | 8 | 10 | 8 | 10 |
| Operating Profit % | 20 % | 16 % | 21 % | 22 % | 21 % | 15 % | 20 % | 20 % |
| Depreciation | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 1 | -1 | 2 | 4 | 4 | 5 | 4 | 6 |
| Tax | 1 | -1 | 0 | 1 | 1 | 2 | 1 | 2 |
| Net Profit | -0 | -0 | 2 | 3 | 3 | 4 | 3 | 4 |
| EPS in ₹ | -0.03 | -0.18 | 0.74 | 1.45 | 1.36 | 1.82 | 1.59 | 2.13 |
Asarfi Hospital
Asarfi Hospital
201.50
+0.50
(0.25%)
Key Fundamentals
Market Cap
396.48 Cr
EPS
5.37
PE Ratio
29.09
Dividend Yield
0.00 %
Industry
Healthcare Services 52 Week High
221.00
52 Week Low
72.90
PB Ratio
4.48
Debt to Equity
0.53
Sector
Hospitals Actual
Company News
View All News
Asarfi Hospital Reports Half-Year Results and Secures ₹4.68 Crore Term Loan for New Cath Lab
8 days ago
8 days agoAsarfi Hospital Limited announced its unaudited standalone and consolidated financial results for the half-year ended September 30, 2025. The company's Board of Directors approved the results at a meeting held on November 10, 2025. The statutory auditors issued an unmodified opinion on the financial statements. During the quarter, the company secured a term loan of ₹4.68 crore from State Bank of India for purchasing and installing a new Cath Lab at Asarfi Hospital, Dhanbad, along with a ₹2.00 crore fund-based Bank Guarantee limit for various empanelments with corporates and PSUs. The company operates in the hospital segment and has a subsidiary named Asarfi Educational Foundation.
Asarfi Hospital Reports Quarterly Results and Secures ₹4.68 Crore Term Loan for New Cath Lab10 days ago
10 days agoAsarfi Hospital Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The company's statutory auditors issued unmodified opinions on both reports. During the quarter, Asarfi Hospital secured a ₹4.68 crore term loan from State Bank of India for purchasing and installing a new Cath Lab at their Dhanbad facility, along with a ₹2.00 crore fund-based Bank Guarantee limit for corporate and PSU empanelments. The standalone results show revenue from operations of ₹35.66 crores for the quarter, with profit after tax of ₹3.19 crores. Basic earnings per share stood at ₹1.62 for the quarter. The consolidated results reported revenue from operations of ₹35.68 crores with profit after tax of ₹3.12 crores and basic earnings per share of ₹1.59.
Asarfi Hospital Reports 56% Revenue Growth and Secures Rs 8.25 Crore Loan for ExpansionAug 07, 2025
Asarfi Hospital Limited reported quarterly results for the quarter ended June 30, 2025, showing strong financial performance. Standalone revenue from operations increased 56% year-over-year to Rs 3,566 lakhs, while consolidated revenue reached Rs 3,568 lakhs. Standalone profit after tax grew 109% to Rs 320 lakhs, and consolidated PAT increased 115% to Rs 312 lakhs. EBITDA margins improved to 20% for both standalone and consolidated results. The company secured loan sanction of Rs 8.25 crores from HDFC Bank, comprising a Rs 5.25 crore term loan for educational building construction and Rs 3 crore working capital loan for Asarfi Cancer Unit expansion. The hospital operates 315 beds across two facilities - a 250-bed Super-Specialty unit and 65-bed Cancer unit. Occupancy rates improved with the Super-Specialty Hospital at 64% versus 57% in the previous year, and Cancer Hospital at 42% versus 24%. The company also signed an MoU with Gleneagles Hospital Chennai to establish Jharkhand's first Multi-Organ Transplant Unit.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,180.90 | #1 1,14,811.40 | 83.67 | 7,184.10 | #1 28.65 | 1,076 | #1 74.34 | 57.09 | |
7,409.00 | 1,06,530.05 | 61.72 | #1 21,994.30 | 14.76 | #1 1,505 | 24.84 | 37.40 | |
925.40 | 69,863.83 | 68.04 | 7,849.70 | 13.25 | 809 | 70.27 | 33.72 | |
2,051.00 | 41,914.40 | 48.80 | 5,575.00 | 12.29 | 790 | 30.03 | 69.23 | |
654.80 | 33,926.56 | 94.45 | 4,286.70 | 15.12 | 337 | 14.65 | 42.68 | |
1,225.50 | 32,940.26 | 58.06 | 3,771.40 | 12.59 | 481 | 21.10 | 40.71 | |
670.65 | 26,835.32 | 75.73 | 3,067.00 | 21.98 | 415 | -40.35 | 40.14 | |
5,996.70 | 15,303.09 | #1 28.77 | 599.90 | 11.69 | 58 | 16.17 | 39.50 | |
1,325.30 | 13,459.63 | 53.31 | 1,566.90 | 17.46 | 244 | -4.30 | 45.04 | |
732.00 | 10,321.21 | 254.74 | 2,257.70 | 17.03 | 49 | 0.00 | 54.07 |
Growth Rate
Revenue Growth
48.78 %
Net Income Growth
152.38 %
Cash Flow Change
-116.69 %
ROE
120.98 %
ROCE
83.68 %
EBITDA Margin (Avg.)
17.71 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2024 | 2025 |
| Total Assets | 154 | 164 |
| Fixed Assets | 94 | 102 |
| Current Assets | 46 | 59 |
| Capital Work in Progress | 0 | 2 |
| Investments | 0 | 0 |
| Other Assets | 60 | 60 |
| Total Liabilities | 154 | 164 |
| Current Liabilities | 44 | 41 |
| Non Current Liabilities | 39 | 42 |
| Total Equity | 70 | 81 |
| Reserve & Surplus | 51 | 61 |
| Share Capital | 20 | 20 |
Cash Flow
| Cash Flow | 2024 | 2025 |
| Net Cash Flow | -1 | 1 |
| Investing Activities | -63 | -7 |
| Operating Activities | 26 | -4 |
| Financing Activities | 36 | 13 |
Share Holding
| % Holding | Mar 2023 | Jul 2023 | Sept 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 83.03 % | 61.17 % | 61.17 % | 61.17 % | 61.17 % | 61.17 % | 61.17 % | 61.17 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.10 % | 0.05 % |
| DIIs | 0.00 % | 0.37 % | 3.25 % | 2.33 % | 1.95 % | 2.92 % | 3.18 % | 2.19 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 23.73 % | 27.40 % | 31.63 % | 32.99 % | 30.86 % | 29.89 % | 30.89 % |
| Others | 16.97 % | 14.74 % | 8.18 % | 4.87 % | 3.89 % | 5.05 % | 5.66 % | 5.70 % |
| No of Share Holders | 37 | 1,248 | 706 | 1,261 | 1,284 | 1,262 | 1,176 | 1,167 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Jan 2024 |  Extraordinary General Meeting | NA | 30 Jan 2024 | 83.07 | 94.14 |
| 13 Sept 2024 |  Annual General Meeting | NA | 13 Sept 2024 | 62.88 | 63.15 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 59.99 | 63.60 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 93.67 | 94.88 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 89.81 | 94.41 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 131.05 | 128.25 |
| 12 Sept 2025 | Annual General Meeting | NA | 12 Sept 2025 | 126.50 | 147.00 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 143.00 | 143.00 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome1 day ago
1 day agoIntimation Of Material Event - Grant Of Accreditation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoSubmission Of Standalone & Consolidated Unaudited Financial Results For The Half Year Ended September 30 20258 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation10 days ago
10 days agoSubmission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended September 30 202510 days ago
10 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On November 10 2025 And Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended September 30202510 days ago
10 days agoIntimation Regarding Credit Rating - Asarfi Hospital Limited.Oct 13, 2025
Oct 13, 2025Closure of Trading WindowOct 11, 2025
Oct 11, 2025Board Meeting Outcome for Intimation Of Appointment Of Cost AuditorSep 25, 2025
Sep 25, 2025Disclosure Regarding Clerical Error In Debtors Ageing Statement In The Financial Statements For The Year Ended March 31 2025Sep 20, 2025
Sep 20, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 13, 2025
Sep 13, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 12, 2025
Sep 12, 2025Reg. 34 (1) Annual Report.Aug 21, 2025
Aug 21, 2025Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) 2015.Aug 20, 2025
Aug 20, 2025Board Meeting Intimation for Intimation Of Board Meeting For Consideration And Approval Of BoardS Report And Notice Of AGM.Aug 12, 2025
Aug 12, 2025Financial Result For Quarter Ended 30Th June2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th August 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 30Th June 2025.Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for Reply To Discrepancy - Reason For Delay In Intimation Of Appointment Of Company Secretary And Compliance OfficerAug 06, 2025
Aug 06, 2025Board Meeting Intimation for Consider And Approve The Unaudited Financial Results Of The Company For The Quarter Ended 30Th June2025.Jul 31, 2025
Jul 31, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 06, 2025
Jun 06, 2025Appointment of Company Secretary and Compliance OfficerJun 04, 2025
Jun 04, 2025Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Appointment Of Compliance Officer Cum Company Secretary.Jun 04, 2025
Jun 04, 2025Integrated Filing (Financial)May 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 09, 2025
May 09, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 08Th May 2025 And Submission Of Standalone & Consolidated Audited Financial Results For The Quarter Ended & Year Ended 31St March 2025 As Per SEBI (Listing Obligations And Disclosure Requirements)May 08, 2025
May 08, 2025Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations 2015.May 02, 2025
May 02, 2025Closure of Trading WindowMar 29, 2025
Mar 29, 2025Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Mar 28, 2025Intimation Of Material Event-High Court Jharkhand Order Civil Litigation Related To Cancer Hospital Land.Mar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 31, 2025
Jan 31, 2025Outcome Of Board Meeting Held On 31St January 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Jan 31, 2025
Jan 31, 2025Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations 2015 To Consider And Approve The Unaudited Financial Results For The Quater Ended 31St Dec2025.Jan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 09, 2024
Nov 09, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Nov 01, 2024Intimation Of Material Event - Possession & Registry Of Land.Nov 01, 2024
Nov 01, 2024Announcement under Regulation 30 (LODR)-Investor PresentationOct 30, 2024
Oct 30, 2024Outcome Of Board Meeting Held On 30Th October, 2024 And Submission Of Unaudited Financial Results For The Half Year Ended 30Th September, 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 30, 2024
Oct 30, 2024Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations, 2015.Oct 22, 2024
Oct 22, 2024Statement Of Deviation Or Variation In The Use Of Proceeds Of Initial Public IssueOct 10, 2024
Oct 10, 2024Announcement Regarding Expansion Of Services Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 10, 2024
Oct 10, 2024Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement) 2015.Oct 07, 2024
Oct 07, 2024Technical Indicators
RSI(14)
Neutral 72.34
ATR(14)
Volatile 12.29
STOCH(9,6)
Overbought 84.22
STOCH RSI(14)
Overbought 89.13
MACD(12,26)
Bullish 5.54
ADX(14)
Strong Trend 32.69
UO(9)
Bearish 52.47
ROC(12)
Uptrend And Accelerating 32.72
WillR(14)
Neutral -23.26
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
